Is Acta dermato-venereologica SCI Indexed? Indexing Status & Metrics

Journal Citation Impact

Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.

Impact Factor

3.40

Citation rate 2.60 1,186 total citations

h5-index 36 h5 depth signal

Cited share 61.4% 294 of 479

Total citations 1,186 Citation footprint

Metric signal 2.36 External metric anchor

Self-citation 3.5% 42 self-citations

Citations Trend

Monthly Publications Cadence

Citing Geographic Demographics

Germany 387

Japan 357

France 307

China 266

Sweden 218

Citing Fields of Research

Dermatology 1,618

Allergies 784

Auto-Inflammatory Disorders 328

Musculoskeletal Disorders 305

Oncology 279

Publishing Activity & Reach

Volume, recency, access pattern, and citing-community signals from the journal analytics record.

All-time article footprint 10,028 Articles tracked across the journal lifetime

Indexed publication set 479 294 cited publications

Last 12 months 307 25.6 publications/month

Open access share 100.0% 307 OA publications in the last year

Leading citing country Germany 387 citing publications

Leading citing field Dermatology 1,618 citing publications

Latest tracked publication 12 October 2026 10 recent records available

Coverage & Indexing History

MEDLINE

v45n1, 1965-

PubMed

v45n1, 1965-

OLDMEDLINE

Active Coverage

Index medicus

Active Coverage

PMC

Active Coverage

Research Focus & Classification

Indexed Subjects

Dermatology Allergies

Broad Categories

Dermatology Sexually Transmitted Diseases Allergies Musculoskeletal Disorders

MeSH Descriptors

Dermatology Sexually Transmitted Diseases

Latest Publications

Recent article records with DOI-first linking and condensed abstracts.

01 12 October 2026

DOI 10.2340/actadv.v106.adv-2026-0779

Molluscum Contagiosum, Warts and Condylomas during JAK Inhibitor Therapy for Atopic Dermatitis: a Retrospective Series of 17 Cases

Open DOI

Giuseppe Russo, Emmanuel Mahé, Florence Tetart et al.

02 12 October 2026

DOI 10.2340/actadv.v106.adv-2026-0665

OX40/OX40L Inhibitors in Atopic Dermatitis: Current Evidence on Short-term Safety

Open DOI

Kian Karimian, Daniel Isufi, Mikkel Bak Jensen et al.

03 7 October 2026

DOI 10.2340/actadv.v106.adv-2026-0822

Haemophagocytic Lymphohistiocytosis Following Severe Erysipelas with EBV Reactivation

Open DOI

Thilo Gambichler, Josefine Brune, Laura Susok

04 7 October 2026

DOI 10.2340/actadv.v106.adv-2025-0166

Invisible Challenges of a Visible Disease: A Qualitative Study on Disease-related Impairment, Participation Barriers and Care Experiences in Adults with Ichthyosis

Open DOI

Jana Stucke, Alina Wacker, Kira Suessmuth et al.

Ichthyoses are rare genodermatoses characterized by scaling, hyperkeratosis, and barrier dysfunction, often accompanied by hypohidrosis and pruritus. Beyond visible symptoms, ichthyosis imposes substantial psychosocial, financial, and ti...

05 7 October 2026

DOI 10.2340/actadv.v106.adv-2026-0765

Efficacy and Safety of Delgocitinib and Its Impact on Patient’s Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study

Open DOI

Elena Pezzolo, Raul Armando Luyo Saboya, Michela Ortoncelli et al.

Delgocitinib is a pan-Janus kinase inhibitor approved for moderate-to-severe chronic hand eczema (CHE) in adults. However, real-world evidence remains limited. We prospectively evaluated 149 adult patients (mean age: 46.4 years; 60.4 % f...

06 6 October 2026

DOI 10.2340/actadv.v106.adv-2026-0919